Vir Biotechnology (NASDAQ:VIR) EVP Mark Eisner Sells 1,889 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Mark Eisner sold 1,889 shares of Vir Biotechnology stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $9.82, for a total value of $18,549.98. Following the completion of the transaction, the executive vice president owned 154,024 shares of the company’s stock, valued at approximately $1,512,515.68. The trade was a 1.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Mark Eisner also recently made the following trade(s):

• On Tuesday, February 24th, Mark Eisner sold 1,616 shares of Vir Biotechnology stock. The stock was sold at an average price of $9.53, for a total value of $15,400.48.
• On Monday, February 23rd, Mark Eisner sold 2,089 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.45, for a total value of $15,563.05.

Vir Biotechnology Price Performance

Shares of VIR stock traded down $0.23 during trading hours on Friday, reaching $9.09. 719,863 shares of the company were exchanged, compared to its average volume of 3,674,494. Vir Biotechnology, Inc. has a fifty-two week low of $4.16 and a fifty-two week high of $10.94. The stock’s fifty day moving average is $6.95 and its two-hundred day moving average is $6.04. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -2.89 and a beta of 1.69.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings data on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.11. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 49.31%. The firm had revenue of $64.07 million during the quarter, compared to analysts’ expectations of $19.91 million. During the same quarter in the previous year, the company posted ($0.76) EPS. Vir Biotechnology’s revenue was up 417.8% on a year-over-year basis. On average, research analysts anticipate that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Key Headlines Impacting Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas strategic collaboration with Vir on the prostate‑cancer asset (VIR‑5500) includes up‑front/near‑term payments and up to about $1.7 billion in contingent milestones — a material de‑risking and commercialization path for a late‑stage asset. Read More.
• Positive Sentiment: Quarterly results beat expectations: Q4 revenue (~$64M) and EPS topped consensus, signaling improving commercial traction and supporting higher analyst enthusiasm. Read More.
• Positive Sentiment: Analyst upgrades and target increases followed the news (Needham raised its target to $18), boosting upside sentiment despite current volatility. Read More.
• Neutral Sentiment: Management will present at investor conferences in early March (TD Cowen, Leerink), which can provide clarity but are not a fundamental catalyst by themselves. Read More.
• Neutral Sentiment: Comparative coverage and peer analyses are increasing visibility and trading volume (e.g., head‑to‑head pieces with peers), but they don’t change Vir’s underlying cash flow or pipeline. Read More.
• Negative Sentiment: Vir priced an underwritten offering of 17,647,058 shares at $8.50 (~$150M gross proceeds). The discounted placement strengthens the balance sheet but is dilutive and increases near‑term share supply, pressuring the stock. Read More.
• Negative Sentiment: Coverage noted the discounted offering as the proximate cause of the post‑rally pullback/tumble, amplifying short‑term selling. Read More.
• Negative Sentiment: Significant insider selling was disclosed (multiple officers and a director reported sales last week), which—combined with the offering—added visible supply and negative sentiment. Read More.

Hedge Funds Weigh In On Vir Biotechnology

Institutional investors and hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. grew its stake in Vir Biotechnology by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock valued at $41,000 after acquiring an additional 1,390 shares during the period. CWM LLC increased its stake in Vir Biotechnology by 23.0% during the 4th quarter. CWM LLC now owns 8,804 shares of the company’s stock worth $53,000 after purchasing an additional 1,646 shares in the last quarter. ProShare Advisors LLC raised its holdings in Vir Biotechnology by 7.8% during the 4th quarter. ProShare Advisors LLC now owns 23,525 shares of the company’s stock worth $142,000 after buying an additional 1,705 shares during the period. Clarius Group LLC lifted its stake in Vir Biotechnology by 0.3% in the third quarter. Clarius Group LLC now owns 619,312 shares of the company’s stock valued at $3,536,000 after buying an additional 1,777 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Vir Biotechnology by 1.0% in the second quarter. Rhumbline Advisers now owns 228,949 shares of the company’s stock valued at $1,154,000 after buying an additional 2,300 shares during the period. Institutional investors and hedge funds own 65.32% of the company’s stock.

Analysts Set New Price Targets

VIR has been the subject of a number of research reports. Barclays lifted their price objective on Vir Biotechnology from $26.00 to $30.00 and gave the stock an “overweight” rating in a research report on Tuesday. Needham & Company LLC boosted their price target on shares of Vir Biotechnology from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday. Evercore restated an “outperform” rating and issued a $18.00 price objective on shares of Vir Biotechnology in a report on Tuesday. Leerink Partners reaffirmed an “outperform” rating and set a $20.00 target price on shares of Vir Biotechnology in a report on Thursday. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Vir Biotechnology in a research report on Tuesday, December 30th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $19.89.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.